Schering-Plough and Oncomethylome collaborate against brain cancer
18th Nov 2005, 14:09 GMT
Schering-Plough is to utilize assay technology from Oncomethylome Sciences in order to evaluate the role of a specific gene in amplifying the effects of Temodar in the treatment of brain cancer.
Schering-Plough and Oncomethylome collaborate against brain cancer related news:
- ERS: Schering Aktiengesellschaft / 9-Monatsbericht 2005 — Presseportal.de Finanzen
- Treatment of Brain Tumors, Discovery and Development of Blood-Brain Barrier (BBB) Penetrating Anthracyclines — Medical News Today RSS/XML Feed
- Innovative Research Set To Push Boundaries Of Cancer Care — ScienceDaily Headlines
- Schering Marketperformer — Finanztreff.de / ANALYSEN
- FDA: Weitere Studie für Schering-Kontrastmittel ... (zwei) — Finanztreff.de / BRANCHEN
- Hubertus Erlen, Chief Executive of German drugmaker Schering ... — Top Stories Photos on Yahoo! News Photos
- Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial — Medical News Today RSS/XML Feed
- FDA: Weitere Studie für Schering-Kontrastmittel Vasovist nötig — Finanztreff.de / TOPTHEMEN
- Blue Brain Power — Computerworld Applications News
- Watching the brain under hypnosis — ZDNet Blogs
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol